Related Experiment Videos

[Effect of immunomodulator AM3 on the exacerbations in patients with chronic bronchitis: a systematic review of

E Reyes Martín1, C Fernández Almendros, J L Alvarez-Sala

  • 1Unidad I+D asociada al Consejo Superior de Investigaciones Científicas, Centro Nacional de Biotecnología, Universidad de Alcalá, Madrid.

Revista Clinica Espanola
|September 25, 2004
PubMed
Abstract

Insights

AM3, an oral immunomodulator, significantly reduces exacerbations and antibiotic use in chronic obstructive pulmonary disease (COPD) patients. This treatment may slow disease progression and improve patient quality of life.

Area of Science:

  • Immunology
  • Pulmonology
  • Pharmacology

Context:

  • Chronic obstructive pulmonary disease (COPD) is a progressive respiratory disease characterized by frequent infectious exacerbations.
  • Exacerbations significantly impact patient quality of life and increase healthcare costs.
  • Current management strategies aim to reduce exacerbation frequency and severity.

Purpose:

  • To systematically analyze the efficacy of AM3, an oral immunomodulator, in reducing exacerbations and antibiotic use in COPD patients.
  • To evaluate the impact of AM3 on the duration of exacerbations and antibiotic treatment courses.

Summary:

  • A systematic review of nine controlled clinical trials demonstrated that AM3 significantly reduced the average number of exacerbations in COPD patients compared to placebo (0.31 units, p < 0.001).
  • Treatment with AM3 also led to significant reductions in the average length of exacerbations (3.10 days, p < 0.001) and antibiotic treatment duration (8.07 days, p < 0.001).
  • While heterogeneity was noted in the duration analyses, the overall findings indicate a clear benefit of AM3 in managing COPD exacerbations.

Impact:

  • AM3 shows clinical effectiveness in preventing COPD exacerbations, potentially slowing respiratory function decline.
  • Reduced exacerbations and antibiotic use may improve the quality of life for COPD patients.
  • This intervention could contribute to decreasing the development of antibiotic resistance.

Related Concept Videos

Asthma III: Clinical Manifestations01:13

Asthma III: Clinical Manifestations

Asthma presents with a characteristic pattern of episodic respiratory symptoms that reflect underlying airway inflammation, bronchoconstriction, and mucus hypersecretion. Although severity varies among individuals, certain clinical manifestations are considered hallmarks of the disorder and often guide diagnosis and assessment.Respiratory SymptomsA persistent cough is one of the most common early features of asthma. It is frequently dry and tends to worsen at night or in the early morning,...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Asthma-III: Symptoms and Complications01:24

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma